Featured Speakers Include

• 

  Carlos CamozziVice President & Chief Medical Officer Amsterdam Molecular Therapeutics

• 

  Robert DerhamPresident CheckOrphan

• 

  Andreas SchuilBusiness Unit Director, Rare Diseases Genzyme

• 

  Frederic RevahChief Executive Officer Genethon

Improve your market access and commercialisation strategies

Seven years after the release of the European Union regulation on Orphan Medicinal Products there has been over 500 orphan designations leading to some 45 orphan drugs been approved for marketing in the EU.

Are you ready to tap into this 35 million patient market?

Of course, it’s not as simple as that. And while it’s true that orphan drugs present a compelling opportunity for industry (and patients), it’s a much more complex picture, fraught with challenges and hurdles to overcome.

We’ve spoken to pharma/biotech companies like Celgene, GSK, Apogenix, Ablynx and Shire as well as  regulatory agencies, and patient organizations. These people working on developing and delivering orphan drugs told us the global trends in this industry and how best to access this 36 million patient market.

They told us that they wanted a meeting that brought together drug developers, regulators and patient organisations to tackle the barriers that are holding back the orphan drug field. From gaining market authorisation and reimbursement to improving patient access to treatments.

The 3^rd Annual Orphan Drug Summit will bring together all of these groups to explore the challenges that are holding your business back and provide you with the key to success in the orphan drug field. 

At the meeting you will: 

• Make lasting business connections and assess new funding opportunities with dedicated 1-2 1 and speed networking sessions 
• Understand effective pricing strategies and discover how they can ensure a return on your investment 
• Hear best practice case studies from industry leaders on the development of comprehensive reimbursement strategies for your orphan drug product
• Apply the lessons that leading pharma and biotech have used to successfully navigate the HTA process and fast track your drug to the market place 
• Forge relationships with multiple attending patient advocacy groups to improve patient access to treatments and allow you to reach market more effectively 
• Gain expert advice on how to encourage investment, secure funding and maximise partnership potential in your orphan drug development

Unlike other orphan drug meetings the World Orphan Drug summit is wholly focused on tackling those barriers that are holding back the orphan drug sector and boasts more patient organizations that any other meeting. We are bringing together the thought leaders in the field for in-depth exploration surrounding pricing, patient access, market exclusivity and clinical development. Therefore every presentation is 100% relevant to you and the work you are doing. 

Who Should Attend:

This meeting has been designed to provide cutting edge, exclusive insights for industry, patient advocacy groups, insurance companies, the venture capital community and academic leaders into how to grow business and drive orphan drug development forward. That means everyone involved in: 

• Regulatory/governmental/public affairs
• Strategy
• Business development/marketing & sales
• Commercial operations
• Patient relations
• Reimbursement/pricing
• Market access
• Clinical R&D
• Scientific/medical affairs
• Health policy

What’s next? 

Visit the resources page to view our colletion of content on Orphan Drugs, available to download for free now.

Something you want to share; white papers, articles or interested in speaking? Then let us know... just email any questions to info@hansonwade.com 

Get the best rates by booking now to ensure your place at this unique meeting - Book online or call +1 212 537 5898.